Sponsor
West China Hospital
Clinical research sponsor
How to interpret these research links
Connected source recordsThe exact organization name West China Hospital appears in 154 distinct published trial records. The links retain registry-reported sponsor and collaborator roles; differently spelled legal entities are not automatically merged. Recruiting status describes the current published registry snapshot, not an independently verified availability guarantee.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
60 shownWireless Wearable Home Prehabilitation for Older Adults With NSCLCNCT07809763 · lead sponsor · 2026-09-10
RECRUITINGMulticenter, Single-Arm, Prospective Phase II Study of Neoadjuvant Cryo-Thermal Ablation Combined With Toripalimab and Chemotherapy for Resectable Stage IB-IIIB Non-Small Cell Lung CancerNCT07855965 · lead sponsor · 2026-09-10
RECRUITINGPre-hepatectomy Rehabilitation in Obese MASLD-Complicated Living Liver Donors With Mazdutide (PRIME)NCT07718126 · lead sponsor · 2026-09-01
RECRUITINGZusanli (ST36) Electroacupuncture Treatment for Neoadjuvant Immunotherapy in Non-Small Cell Lung CancerNCT07076836 · lead sponsor · 2026-08-31
RECRUITINGAkkermansia Muciniphila (AKK) for Radiation-Induced Skin InjuryNCT07635277 · lead sponsor · 2026-06-07
RECRUITINGIMP3-saRNA Vaccine in Advanced NSCLCNCT07561723 · lead sponsor · 2026-04-30
RECRUITINGMDT-Based Umbrella Decision Model for Geriatric Lung Cancer PatientsNCT07509333 · lead sponsor · 2026-04-05
RECRUITINGThe Construction and Clinical Application of an Integrated Perioperative Management System for Lung Cancer Based on Wearable Devices and Intelligent PlatformsNCT07310056 · lead sponsor · 2026-01-01
RECRUITINGA Study of GV20-0251 in Advanced or Refractory Solid TumorsNCT07106827 · lead sponsor · 2025-09-04
RECRUITINGHepatic Arterial Infusion Chemotherapy (HAIC) Combined With Durvalumab and Lenvatinib in Patients With Locally Advanced or Metastatic Intrahepatic Cholangiocarcinoma: a Phase 2 Study(HAIC-quad Trial)NCT06859684 · lead sponsor · 2025-03-01
RECRUITINGSBRT Combined With PD-1 Inhibitor and Chemotherapy in Early-stage TNBCNCT06627712 · lead sponsor · 2024-11-01
RECRUITINGAI App for Management of Atopic DermatitisNCT06362629 · lead sponsor · 2024-09-01
RECRUITINGIdentifying Local Field Potential Biomarkers for Treatment-Resistant Major Depression With Deep Brain StimulationNCT06542094 · lead sponsor · 2024-08-03
RECRUITINGAssessment System of Sarcopenia in Lung Cancer PatientsNCT06327594 · lead sponsor · 2023-11-01
RECRUITINGStudy of Camrelizumab Plus Apatinib and Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)NCT05447702 · lead sponsor · 2022-11-01
RECRUITINGPSMA PET/CT-Guided SBRT Plus Darolutamide in mHSPCNCT07649421 · lead sponsor · 2026-09-15
NOT_YET_RECRUITINGSurgery vs. No Surgery for Primary Tumor in De Novo Stage IV Breast Cancer With Solitary Bone MetastasesNCT07687225 · lead sponsor · 2026-09-01
NOT_YET_RECRUITINGDigital Rehabilitation With Wearable Monitors for Sequential Lung Cancer ResectionNCT07797075 · lead sponsor · 2026-08-31
NOT_YET_RECRUITINGRehabilitation With Wearable Monitors for Post-Lung Cancer SurgeryNCT07733492 · lead sponsor · 2026-08-31
NOT_YET_RECRUITINGUnderdilated VCX-TIPS Versus EVL Plus NSBB for Secondary Prophylaxis of Variceal Bleeding in CirrhosisNCT07587671 · lead sponsor · 2026-08-01
NOT_YET_RECRUITINGExploratory Study on the Treatment of EB Virus Positive HIV Associated Lymphoma With EBV mRNA VaccineNCT07563023 · lead sponsor · 2026-05-01
NOT_YET_RECRUITINGThe Comparison Between DEDTI BR and T/E BRNCT07593846 · lead sponsor · 2026-05-01
NOT_YET_RECRUITINGInfluencing Factors and Mechanisms of Capsular Contracture After Prosthesis Reconstruction in Patients With Breast CancerNCT07419971 · lead sponsor · 2026-03-01
ENROLLING_BY_INVITATIONCellular-Level Fluorescence Imaging for Intraoperative Margin Assessment in Breast CancerNCT07311317 · lead sponsor · 2026-01-01
NOT_YET_RECRUITINGSKB264 Combined With KL-A167 Neoadjuvant Therapy for Early-stage, High-risk ER+/HER2- Breast CancerNCT07109284 · lead sponsor · 2025-09-01
NOT_YET_RECRUITINGClinical Outcomes of Tislelizumab Combined With Chemotherapy as Induction Therapy in Stage III (cTNM-IIIB/IIIC) NSCLCNCT06829641 · lead sponsor · 2025-08-09
NOT_YET_RECRUITINGNeoadjuvant Ensartinib in ALK Positive Resectable Stage II to III Non-Small Cell Lung CancerNCT06779539 · lead sponsor · 2025-01-15
NOT_YET_RECRUITINGNeoadjuvant Chemoimmunotherapy in Stage IIIA- N2IIIB Non-small Cell Lung CancerNCT06394427 · lead sponsor · 2024-05-01
UNKNOWNDecade-Long Insights Into Transperineal Prostate Biopsy in a West China PopulationNCT06366308 · lead sponsor · 2024-04-15
UNKNOWNPreemptive TIPS for Gastric Variceal Bleeding in Patients With CirrhosisNCT06122792 · lead sponsor · 2024-01-01
NOT_YET_RECRUITINGPreemptive TIPS for Variceal Bleeding in Cirrhotic Patients With Occlusive Portal Vein ThrombosisNCT06122753 · lead sponsor · 2024-01-01
NOT_YET_RECRUITINGPre-operative Antihypertension Strategies-Carotid Artery StentingNCT05905848 · lead sponsor · 2023-06-15
UNKNOWNDisitamab Vedotin(RC48) Combined With Penpulimab(AK105) for Neoadjuvant Treatment of HER2-low Breast CancerNCT05726175 · lead sponsor · 2023-03-01
UNKNOWNMachine Learning-based Models in Prediction of DVT and PTE in AECOPD PatientsNCT05905874 · lead sponsor · 2023-01-01
UNKNOWNCarvedilol vs. Propranolol in Second Prophylaxis of Variceal BleedingNCT05651789 · lead sponsor · 2023-01-01
UNKNOWNAlmonertinib Therapy in Patients With Abnormal Liver Function After EGFR-TKI Treatment, or Almonertinib First-line Therapy in Patients With Basic HepatopathyNCT05662813 · lead sponsor · 2022-11-09
UNKNOWNIncidence and Predictors of Post-TIPS Heart Failure in Patients With CirrhosisNCT05596253 · lead sponsor · 2022-10-11
UNKNOWNA Phase II Clinical Study of Stereotactic Radiation Therapy in Patients With High-risk Prostate CancerNCT05430737 · lead sponsor · 2022-06-30
UNKNOWNDifferential Regulation of miRNA and Protein in Human Plasma Extracellular Vesicles by Different Types of Exercise.NCT06609785 · lead sponsor · 2022-06-01
COMPLETEDTQB3616 Capsules Combined With Abiraterone Acetate Plus Prednisone in Metastatic Castration-Resistant Prostate CancerNCT05156450 · lead sponsor · 2022-01-01
UNKNOWNβ-hydroxy-β-methylbutyrate-enriched Nutritional Supplements for Obesity AdultsNCT04953936 · lead sponsor · 2021-09-20
UNKNOWNA Multi-omics Study of Metastatic Prostate Cancer (MOSMPCA)NCT04660617 · lead sponsor · 2021-08-01
UNKNOWNNeoadjuvant Therapy of Abiraterone Plus ADT for Intraductal Carcinoma of the ProstateNCT04736108 · lead sponsor · 2021-05-01
UNKNOWNCharacteristics, Treatment, and Economic Burden of Patients With CVD,CKD or at High Cardiovascular RiskNCT03958760 · lead sponsor · 2021-02-28
COMPLETEDA Study on the Effectiveness of WeChat-based Online Education to Reduce Perioperative Anxiety in Breast Cancer PatientsNCT05291494 · lead sponsor · 2021-02-01
COMPLETEDSingle-arm, Multi-center Clinical Study of Pyrotinib Maleate Tablets Combined With Albumin-bound Paclitaxel and Trastuzumab in Neoadjuvant Treatment of Her2-positive Early or Locally Advanced Breast CancerNCT04917900 · lead sponsor · 2020-12-01
UNKNOWNNeoadjuvant Chemotherapy and Tilelizumab in Stage III（cTNM-IIIA.IIIB）Non-small-cell Lung CancerNCT04865705 · lead sponsor · 2020-11-10
UNKNOWNPyrotinib Maleate Tablets Combined With Albumin Paclitaxel and Trastuzumab for Her2-positive Breast CancerNCT04152057 · lead sponsor · 2019-11-01
UNKNOWNShenlingcao Oral Liquid for Patients With Stage II or IIIA NSCLCNCT03712969 · lead sponsor · 2018-11-05
COMPLETEDMagnetic Resonance Technics for the Assessment of Liver Function Before and After TIPSNCT03933891 · lead sponsor · 2018-08-28
UNKNOWNReal-World Study on Adjuvant Therapy Combined With Shenlingcao Oral Liquid in Patients for Stage II and IIIA Non-small Cell Lung Cancer After Radical ResectionNCT03479294 · lead sponsor · 2018-03-28
TERMINATEDComparison Between Wedge Resection and Segmentectomy for Ground Glass Opacity- Dominant Stage IA NSCLCNCT02718365 · lead sponsor · 2017-12-07
UNKNOWNA Study to Evaluate Clinical Characteristics of Lung Cancer in Patients With Surgeries and Adjuvant TherapiesNCT03421093 · lead sponsor · 2017-12-01
COMPLETEDDocetaxel Versus Abiraterone as First-line Treatment in mCRPC Patients With Intraductal Carcinoma of the ProstateNCT03356444 · lead sponsor · 2017-11-01
UNKNOWNDynamic Monitoring Circulating Tumor DNA in Surgical Patients With Lung CancerNCT03317080 · lead sponsor · 2017-09-27
UNKNOWNUltrasound Evaluation of Gastric Emptying in Diabetic Patients: a Comparison With Non-diabetic ControlsNCT03217630 · lead sponsor · 2017-07-01
COMPLETEDApatinib Combine With Platinum-Based Doublet Chemotherapy for First-line Treatment of Advanced NSCLCNCT03201146 · lead sponsor · 2017-06-27
UNKNOWNUltrasound Evaluation of Gastric Emptying in Diabetic PatientsNCT03187145 · lead sponsor · 2017-06-15
UNKNOWNLow Molecular Weight Heparin for the Prevention of Early TIPS DysfunctionNCT03171727 · lead sponsor · 2017-06-01
UNKNOWNThe Use of Propranolol for the Prevention of Worsening of Esophageal Varices in Patients With Isolated Gastric VaricesNCT03171805 · lead sponsor · 2017-06-01
UNKNOWNDrugs studied in this sponsor's trials
30 mapped RxNorm conceptsThese drug records are connected through ClinicalTrials.gov studies listing West China Hospital as a sponsor, collaborator or responsible party. Each count is the number of distinct trials containing the mapped drug intervention. This does not establish that the organization manufactures, owns, sells or developed the drug.
propranolol4
lauromacrogols3
abiraterone acetate2
ensartinib2
hydrochlorothiazide2
toripalimab2
amlodipine1
aspirin1
propranolol RxCUI 8787 · Lead sponsor in 4 linked trial(s) · 0 currently recruiting
4 trials
lauromacrogols RxCUI 386055 · Lead sponsor in 3 linked trial(s) · 0 currently recruiting
3 trials
abiraterone acetate RxCUI 1100071 · Lead sponsor in 2 linked trial(s) · 0 currently recruiting
2 trials
ensartinib RxCUI 2712546 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting
2 trials
hydrochlorothiazide RxCUI 5487 · Lead sponsor in 2 linked trial(s) · 0 currently recruiting
2 trials
toripalimab RxCUI 2669406 · Lead sponsor in 1 linked trial(s) · 2 currently recruiting
2 trials
amlodipine RxCUI 17767 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting
1 trial
aspirin RxCUI 1191 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting
1 trial
bevacizumab RxCUI 253337 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting
1 trial
carvedilol RxCUI 20352 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting
1 trial
cyclophosphamide RxCUI 3002 · Lead sponsor in 1 linked trial(s) · 1 currently recruiting
1 trial
docetaxel RxCUI 72962 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting
1 trial
durvalumab RxCUI 1919503 · Lead sponsor in 1 linked trial(s) · 1 currently recruiting
1 trial
epirubicin RxCUI 3995 · Lead sponsor in 1 linked trial(s) · 1 currently recruiting
1 trial
erlotinib RxCUI 337525 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting
1 trial
gefitinib RxCUI 328134 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting
1 trial
goserelin RxCUI 50610 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting
1 trial
idebenone RxCUI 51296 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting
1 trial
indapamide RxCUI 5764 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting
1 trial
lenvatinib RxCUI 1603296 · Lead sponsor in 1 linked trial(s) · 1 currently recruiting
1 trial
levofloxacin RxCUI 82122 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting
1 trial
nitrendipine RxCUI 7441 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting
1 trial
paclitaxel protein-bound RxCUI 486610 · Lead sponsor in 1 linked trial(s) · 1 currently recruiting
1 trial
penpulimab RxCUI 2712542 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting
1 trial
Sponsor roles
lead sponsor82
collaborator72
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.